SCHEMBL2038516

SCHEMBL2038516

Oc1ccc(I)cc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1477169 0.79 — —
SCHEMBL764585 0.75 — —
SCHEMBL80458 0.75 — —
SCHEMBL29438797 0.75 — —
SCHEMBL29481423 0.75 — —
Fluoride SCHEMBL25169957 0.72 CES2 (0.39) —
SCHEMBL185204 0.72 — —
SCHEMBL2453961 0.72 — —
SCHEMBL857363 0.72 ESR1 (0.68) —
SCHEMBL1686442 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4003988-B1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS SERVIER LAB (FR) 2026-05-20 — — EP disclosed
US-20260125410-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS UNIV YALE (US) 2026-05-07 — — US disclosed
US-12570648-B2 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer LES LABORATOIRES SERVIER (FR) 2026-03-10 — — US disclosed
US-20260027220-A1 EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2026-01-29 — — US disclosed
EP-3891149-B1 RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2026-01-28 — — EP disclosed
US-20250387504-A1 ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2025-12-25 — — US disclosed
US-20250388614-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS UNIV YALE (US) 2025-12-25 — — US disclosed
EP-4658263-A2 COMPOUNDS AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING ARTHRITIS Yale University (US) 2025-12-10 — — EP disclosed
US-12485178-B2 Bifunctional small molecules to target the selective degradation of circulating proteins YALE UNIVERSITY (US) 2025-12-02 — — US disclosed
US-20250339547-A1 MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF NOVARTIS AG (CH) 2025-11-06 — — US disclosed
WO-2011073112-A2 MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION UNIVERSITY OF BASEL (CH) 2011-06-23 — — WO disclosed
WO-2011073112-A2 MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION UNIVERSITY OF BASEL (CH) 2011-06-23 — — WO disclosed
WO-2010136036-A2 CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS LEO PHARMA A/S (DK) 2010-12-02 — — WO disclosed
WO-2010136036-A2 CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS LEO PHARMA A/S (DK) 2010-12-02 — — WO disclosed
US-20100130559-A1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-05-27 — — US disclosed
US-20100113776-A1 PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO.,LTD. (JP) 2010-05-06 — — US disclosed
EP-2098517-A1 NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-09 — — EP disclosed
CN-101208334-A Novel cyclic amines HOFFMANN LA ROCHE (CH) 2008-06-25 — — CN disclosed
EP-0409634-A2 Liquid crystal compounds and optically active compounds SANYO CHEMICAL INDUSTRIES LTD. (JP) 1991-01-23 — — EP disclosed
US-4921632-A Liquid crystal compounds and compositions NEC CORPORATION (JP) 1990-05-01 — — US disclosed
Send feedback